Analytical Data
-
Gene name
CAPN9
- Application
-
Alternative Names
GC36; nCL4; Novel Calpain Large Subunit-4; Digestive tract-specific calpain; New calpain 4
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O14815
-
Expression Region
Leu42~Ala340
-
Molecular Weight
37kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CAPN9, a member of the calpain family of calcium-dependent cysteine proteases, has garnered significant attention in recent years due to its potential roles in various cellular processes such as apoptosis, cell differentiation, and migration. Research indicates that CAPN9 is expressed predominantly in specific tissues and may play a critical role in the progression of certain cancers, particularly those related to the digestive system. Its aberrant expression has been linked to tumorigenesis and poor prognosis in several malignancies. Moreover, CAPN9 is thought to participate in the regulation of the immune response and inflammatory processes, making it a potential target for therapeutic interventions. With advances in recombinant protein technology, researchers are now able to produce CAPN9 in larger quantities and with higher purity, facilitating detailed biochemical studies. These studies aim to elucidate its enzymatic activity, regulation, and interaction with other cellular proteins, which could pave the way for new strategies in cancer therapy and the management of inflammatory diseases. Understanding the molecular mechanisms underlying CAPN9 function will provide valuable insights into its role in health and disease, potentially leading to the development of novel diagnostic and prognostic markers.
